|Day Low/High||91.69 / 92.99|
|52 Wk Low/High||29.51 / 99.28|
Shareholders of the oncology drug maker ought to be satisfied with the auction's conclusion.
Overall, this is still a good environment for stock picking.
Acquiring Medivation will strengthen Pfizer's oncology franchise, which has lost ground in recent years to some Big Pharma competitors.
Bears continue to have a tough time gaining traction.
There is hesitancy to chase, especially with the FOMC rate decision this afternoon.
Cramer says don't buy Tesaro but do buy Cirrus Logic.
Cramer says discipline is needed to start trimming positions and taking profits.
Keep in mind that strong action like this tends to create underlying support.
In most cases ovarian cancer recurs within two years after chemotherapy, but the Tesaro (TSRO) drug stops that, Dr. Marc Siegel explained on Fox Business today.
Tesaro (TSRO) stock is falling this morning despite the success of its cancer drug trial after it announced an offering of $300 million worth of common stock to the public.
Here are Thursday's top research calls, including upgrades for General Mills, Priceline, PulteGroup and Yelp.
Sanofi's $52.50 per share takeout offer for Medivation is looking increasingly unappealing.
Tesaro (TSRO) reported positive results of a clinical trial for an ovarian cancer drug.
Here's a technical look at how to trade some of the most active stocks on the market right now.
Besides Sanofi, Biogen is the next most likely to complete a sizable transaction in the next 12 months, according to Credit Suisse analysts.